{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.68 vs. cons $7.59",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Cigna Healthcare Medical Care Ratio (MCR)",
      "prediction": "BEAT",
      "answer": "pred ~84.6% vs. cons 85.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$70.6B vs. cons $70.5B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$30.55 vs. cons $30.45 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Cigna Healthcare FY2026 MCR range",
      "prediction": "UNCHANGED",
      "answer": "guide ~84.2% vs. cons 84.2% (FY2026, midpoint of reiterated 83.7%-84.7% range)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Cigna Healthcare FY2026 pre-tax earnings",
      "prediction": "BETTER",
      "answer": "guide ~$4.55B vs. cons $4.525B (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "EPS beat and favorable MCR should spark an initial pop, but with FY26 EPS guidance only nudged higher (not a UNH-style meaningful raise) and full-year MCR range left unchanged, CI risks the 'good-not-great' treatment the sector gave HUM/ELV this cycle. Back-half Signature PBM investment spend and unresolved eviCore/ACA-exit timing cap out-period estimate revisions, so sell-side models likely trim 2H26/FY27 PBS and modestly increase Cigna Healthcare cost-trend assumptions even after a headline beat, pulling the initial gain back in over the week.",
  "day5_confidence": "LOW"
}